CLONING GENES WITH AN EPISOMAL VECTOR

用附加载体克隆基因

• 批准号: 3198868
• 负责人: ROBERT T SCHIMKE
• 金额: $ 21.57万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1991
• 资助国家: 美国
• 起止时间: 1991-05-01 至 1994-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3198868
• 关键词: R factors; ataxia telangiectasia; biological transport; complementary DNA; cytogenetics; flow cytometry; gene complementation; gene duplication; gene mutation; genetic manipulation; genetic techniques; genetic transcription; genome; human genetic material tag; human tissue; methotrexate; molecular cloning; molecular genetics; nucleic acid sequence; transfection; transposon /insertion element

DESCRIPTION: (Adapted from Investigator's Abstract) This research proposal involves the development of a mammalian vector system that replicates episomally and the development of new methods for the insertion of cDNA libraries into it. Because the vector remains episomal, it can be recovered rapidly and readily. In this respect it differs from previously described vectors that integrate rapidly into the host (human) cell genome, and hence, cannot be recovered readily. This system can be used to complement defective functions of human cells where the gene is unknown and where a selection can be imparted. Part of the proposal is to continue development of the vector system. Additionally the investigators propose to identify human genes which have not previously been identified: 1) Ataxia telangiectasia, specifically complementation group D; 2) gene(s) coding for methotrexate transport, genes which in a defective form result in a common form of methotrexate resistance in cancer cells.

描述：（改编自研究者摘要）本研究提案 涉及哺乳动物载体系统的发展， 游离型和开发插入cDNA的新方法 因为载体保持游离型，所以它可以是 迅速而迅速地恢复。 在这方面，它不同于以前 描述了快速整合到宿主（人）细胞基因组中的载体， 因此不能容易地回收。 该系统可用于 基因未知的人类细胞的补体缺陷功能， 在那里可以进行选择。 部分提议是继续 载体系统的发展。 此外，研究人员建议 识别以前未被识别的人类基因：1） 共济失调毛细血管扩张症，特别是互补组D; 2）基因 编码甲氨蝶呤转运的基因， 在癌细胞中甲氨蝶呤耐药的一种常见形式。